Click Therapeutics is developing digital treatments for multiple diseases, disorders and problems. They have an FDA cleared app for smoking cessation plus many other applications under development. They have partnered with Otsuka Pharma to create a prescription digital therapeutic (PDT) for major depressive disorder, and partnered with Boehringer Ingelheim for a PDT to treat schizophrenia.
About Digital Therapeutics
The Digital Therapeutics Alliance defines Digital Therapeutics as products that “deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease.” Digital Therapeutics are sometimes referred to as “DTx” or as Prescription Digital Therapeutics, “PDT”. While there are digital therapeutics that are direct-to-consumer, most digital therapeutics are submitting the software to the FDA to clear as an SaMD, which stands for “Software as a Medical Device”.